We are live on ! Find out more
LJPC

La Jolla Pharmaceutical Company

Delisted

LJPC was delisted on the 19th of August, 2022.

72 hedge funds and large institutions have $447M invested in La Jolla Pharmaceutical Company in 2015 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 31 increasing their positions, 12 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

633% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 3

158% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 12

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

96% more call options, than puts

Call options by funds: $4.65M | Put options by funds: $2.37M

68% more capital invested

Capital invested by funds: $266M → $447M (+$180M)

36% more funds holding

Funds holding: 5372 (+19)

Holders
72
Holders Change
+19
Holders Change %
+35.85%
% of All Funds
2.01%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.11%
New
22
Increased
31
Reduced
12
Closed
3
Calls
$4.65M
Puts
$2.37M
Net Calls
+$2.28M
Net Calls Change
+$1.02M
Name Holding Trade Value Shares
Change
Change in
Stake
TCM
1
Tang Capital Management
California
$81M +$7.88M +250,000 +9%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$74.2M +$12.1M +382,500 +17%
BC
3
Broadfin Capital
New York
$30.4M +$10.6M +335,903 +44%
RI
4
RTW Investments
New York
$30M +$25.1M +796,631 +281%
Franklin Resources
5
Franklin Resources
California
$25.3M -$2.29M -72,700 -7%
JHIU
6
Janus Henderson Investors US
Colorado
$23.8M +$27M +855,572 New
ACA
7
Avoro Capital Advisors
New York
$22.4M +$6.06M +192,300 +31%
PA
8
Perceptive Advisors
New York
$18.2M +$12.7M +401,600 +159%
VAM
9
Visium Asset Management
New York
$17.5M +$596K +18,900 +3%
Allianz Asset Management
10
Allianz Asset Management
Germany
$13M +$14.7M +467,797 New
Vanguard Group
11
Vanguard Group
Pennsylvania
$12M +$1.7M +54,035 +14%
BBA
12
Baker Bros. Advisors
New York
$11.4M
BFA
13
BlackRock Fund Advisors
California
$9.9M +$1.68M +53,455 +18%
BIT
14
BlackRock Institutional Trust
California
$8.73M +$3.23M +102,520 +48%
Morgan Stanley
15
Morgan Stanley
New York
$8.32M +$5.47M +173,726 +138%
GIM
16
Granahan Investment Management
Massachusetts
$5.9M +$2.78M +88,131 +71%
State Street
17
State Street
Massachusetts
$4.7M +$2.35M +74,421 +79%
Deutsche Bank
18
Deutsche Bank
Germany
$4.04M +$2.98M +94,427 +186%
Northern Trust
19
Northern Trust
Illinois
$3.92M +$3.17M +100,450 +246%
IHM
20
Iguana Healthcare Management
New York
$3.47M +$3.94M +125,000 New
ACP
21
Acuta Capital Partners
California
$3.4M +$3.85M +122,222 New
EI
22
EAM Investors
California
$2.71M +$3.07M +97,350 New
Geode Capital Management
23
Geode Capital Management
Massachusetts
$2.61M +$845K +26,824 +40%
Asset Management One
24
Asset Management One
Japan
$2.36M +$2.89M +91,823 New
SM
25
Sabby Management
Florida
$2.36M +$2.68M +85,011 New

LJPC Hedge Fund Activity: Q3 2015 in Review

72 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q3 2015, worth a combined $447M — up 68% from $266M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new LJPC positions and 3 closed out — a net gain of 19 holders — while 31 added to existing stakes and 12 trimmed.

The largest buyer was Janus Henderson Investors US, opening a new position worth an estimated $27M. The largest seller was D.E. Shaw & Co, cutting an estimated $2.66M.

  • 72 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q3 2015, up from 53 in Q2 2015.
  • Funds reported $447M of La Jolla Pharmaceutical Company stock for Q3 2015, up 68% quarter-over-quarter.
  • 22 funds opened new La Jolla Pharmaceutical Company positions in Q3 2015 and 3 closed out, a net change of +19 holders.
  • The largest La Jolla Pharmaceutical Company buyer in Q3 2015 was Janus Henderson Investors US, an estimated $27M added.
  • The largest La Jolla Pharmaceutical Company seller in Q3 2015 was D.E. Shaw & Co, an estimated $2.66M sold.

Based on aggregated 13F filings for Q3 2015.